Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 12/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287523 | 0.95 | MAPT (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL13705304 | 0.93 | HCRTR1 (0.33) | HCRTR1HCRTR2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4285549 | 0.90 | HCRTR1 (0.35) | HCRTR1HCRTR2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4281558 | 0.90 | HCRTR1 (0.42) | HCRTR1HCRTR2CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL13705305 | 0.89 | MAPT (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL4296784 | 0.88 | HCRTR1 (0.31) | HCRTR1HCRTR2 | |
| SCHEMBL4286204 | 0.86 | CHKA (0.33) | HCRTR1HCRTR2 | |
| SCHEMBL4290997 | 0.86 | HTR7 (0.34) | — | |
| SCHEMBL4291716 | 0.85 | HCRTR1 (0.35) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL4293922 | 0.84 | NOS2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885CYP3A4 50/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885CYP3A4 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.